Skip to main content
OpenTrials
Completed

NCT Number: NCT02565732

Safety and Efficacy of Botulinum Toxin Type A Topical Gel for Primary Axillary Hyperhidrosis

This is a safety and efficacy study of botulinum toxin type A in subjects with primary axillary hyperhidrosis.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Primary location

San Francisco, California, 94117, United States

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Primary axillary hyperhidrosis
  • Female or male, 18 years of age or older in good general health
  • Excessive sweating interferes with daily life activities and scores 3 or 4 on the HDSS at Screening and Baseline
  • Axillary sweat production of at least 50 mg/5 min measured gravimetrically

Exclusion criteria

  • Any neurological condition, that may place the subject at increased risk with exposure to botulinum toxin type A such as amyotrophic lateral sclerosis and motor neuropathy, Lambert-Eaton syndrome, and Myasthenia gravis
  • Muscle weakness or paralysis, particularly in the upper extremities
  • Active skin disease or irritation or disrupted barrier at the treatment area
  • Undergone any procedures which may affect the axillary areas
  • Treatment with botulinum toxin type A in the axilla in the last 9 months or anywhere in the body in the last 6 months
  • Any prior axillary use of an anti-hyperhidrosis medical device
  • If menopausal had symptoms of menopause such as sweating or flushing within the last year

Treatment and study plan

Botulinum toxin type A

Biological

Botulinum toxin type A, Dose A, Topical

Placebo comparator

Biological

Placebo, Dose C, Topical

Primary outcomes

  1. Hyperhidrosis Disease Severity Scale (HDSS)

    Time frame: Week 4

    Improvement at follow-up in the experimental groups compared to the placebo group

  2. Gravimetry

    Time frame: Week 4

    The amount of sweat measured gravimetrically

Secondary outcomes

  1. Dermatology Life Quality Index (DLQI)

    Time frame: Week 4

Sponsors and collaborators

Lead sponsor

Revance Therapeutics, Inc.

Industry

Registry information

Important dates

Study start
2015
Primary completion
2015
Study completion
2016
First posted
Oct 1, 2015
Registry last updated
Aug 4, 2016

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.